MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Maker of Centrifuge Devive to Derive Platelet-Rich-Plasma Raises $3M

Wound-healing company Cytomedix, which makes the AutoloGel would healing system, raises $3 million

Cytomedix, creator of the Autologel system, has raised $3 million, according to a recent regulatory filing.

The AutoloGel system comprises a centrifuge, a wound dressing kit and a reagent kit. The centrifuge is used to derive platelet-rich-plasma from a patient's blood that is widely known to accelerate wound healing. 

Cytomedix was formerly known as Autologous Wound Therapy Inc. On Dec. 2, the company announced that the Centers for Medicare and Medicaid Services has enhanced the reimbursement for its wound healing technology.

CMS decided that the reimbursement code to which AutoloGel is assigned be paid at a national average rate of $411 under the Hospital Outpatient Prospective Payment System.

"We are pleased that CMS has responded positively to the information made available to the agency in the public comment process and established a 2014 payment rate which is an approximate five fold improvement over the initial proposed payment level,” said Martin Rosendale, Chief Executive Officer of Cytomedix, in the release.

Cytomedix, which is a public company, had revenue of $2.9 million in the third quarter, up 72% from$1.7 million in the third quarter of 2012. However, it widened its loss to 5 million, or 5 cents per share in the third quarter, from a loss of $3.8 million, or 4 cents per share in the same quarter a year ago.

 -- By Arundhati Parmar, Senior Editor, MD+DI
[email protected]

 

Filed Under
500 characters remaining